27.05.2025 14:00:00

Is Pfizer Stock a Buy After This $1.25 Billion Investment?

Pfizer (NYSE: PFE) made a fortune thanks to its work in the COVID-19 market. In 2022, it became the first company in the biopharmaceutical industry to generate $100 billion in annual sales.However, the pandemic receded, and revenue in this area dropped off a cliff. The drugmaker has been looking for a way back ever since -- a product, or several, that can rack up billions in annual sales and help its top line move consistently in the right direction.It recently found a candidate for that position. Let's look deeper, and discuss whether the recent development makes Pfizer stock a buy.Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Analysen zu Pfizer Inc.mehr Analysen

21.05.25 Pfizer Buy Jefferies & Company Inc.
29.04.25 Pfizer Buy Jefferies & Company Inc.
29.04.25 Pfizer Neutral JP Morgan Chase & Co.
29.04.25 Pfizer Neutral UBS AG
14.04.25 Pfizer Buy Jefferies & Company Inc.

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Pfizer Inc. 20,53 -1,51% Pfizer Inc.
pagehit